EVH — Evolent Health, Inc

Is EVH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Overbought As of August 19, 2026

Evolent Health, Inc (EVH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $4.58. The rating moved from Neutral to Overbought on August 11, 2026.

See all overbought Healthcare stocks →

AI analysis

Evolent Health sits at the intersection of payers' need for care-management, risk-adjustment and analytics, giving it structural demand upside as insurers push data/AI capabilities to defend margins. The company benefits from recurring contract revenue and secular tailwinds toward outsourced population-health platforms, but outcomes depend heavily on client retention, contract economics and the ability to commercialize higher-margin analytics offerings. Near-term valuation appears discounted, creating upside if management demonstrates sustained margin improvement and new contract wins; downside scenarios include client churn, liquidity stress or tougher competition.

Key factors

  • Established position as a services/platform provider to payers and providers with recurring revenue streams and contract-based relationships.
  • Sector-level push toward data, analytics and AI governance creates demand tailwinds for care-management, risk-adjustment, and analytics platforms.
  • Opportunity to convert payer interest in margin optimization into multi-year engagements and upsell of higher‑margin analytics/technology offerings.
  • Near-term valuation is depressed versus growth peers, leaving room for upside on positive execution or contract wins.
  • Market tone is mildly risk-on and growth-oriented, which can favor beaten-down, growth-exposed healthcare technology names if momentum resumes.

Risks

  • Customer concentration and contract risk with a small number of large payer customers could cause sharp revenue volatility if contracts renegotiate or are lost.
  • Liquidity and leverage pressures if free cash flow underperforms expectations and capital markets remain constrained.
  • Execution risk integrating advanced analytics/AI into product offerings and converting pilot relationships into scaled, profitable contracts.
  • Regulatory and reimbursement changes that alter payer economics or reduce demand for outsourced care-management services.
  • Intense competition from large incumbents, consulting firms, and new tech entrants offering analytics, cloud, or end-to-end population health solutions.
  • Macro sensitivity: slower elective care cycles, lower MA enrollment growth, or adverse rate moves that affect valuation and funding costs.

See today's live rating, score and targets

Members see the live hourly rating for EVH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.